Engineering strategies of Anti-HIV antibody therapeutics in clinical development
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
PURPOSE OF REVIEW: Anti-human immunodeficiency virus (HIV) antibody-based therapeutics offer an alternative treatment option to current antiretroviral drugs. This review aims to provide an overview of the Fc- and Fab-engineering strategies that have been developed to optimize broadly neutralizing antibodies and discuss recent findings from preclinical and clinical studies.
RECENT FINDINGS: Multispecific antibodies, including bispecific and trispecific antibodies, DART molecules, and BiTEs, as well as Fc-optimized antibodies, have emerged as promising therapeutic candidates for the treatment of HIV. These engineered antibodies engage multiple epitopes on the HIV envelope protein and human receptors, resulting in increased potency and breadth of activity. Additionally, Fc-enhanced antibodies have demonstrated extended half-life and improved effector function.
SUMMARY: The development of Fc and Fab-engineered antibodies for the treatment of HIV continues to show promising progress. These novel therapies have the potential to overcome the limitations of current antiretroviral pharmacologic agents by more effectively suppressing viral load and targeting latent reservoirs in individuals living with HIV. Further studies are needed to fully understand the safety and efficacy of these therapies, but the growing body of evidence supports their potential as a new class of therapeutics for the treatment of HIV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current opinion in HIV and AIDS - 18(2023), 4 vom: 01. Juli, Seite 184-190 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pihlstrom, Nicole [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Bispecific |
|---|
| Anmerkungen: |
Date Completed 07.06.2023 Date Revised 03.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/COH.0000000000000796 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35647786X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35647786X | ||
| 003 | DE-627 | ||
| 005 | 20231226070539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/COH.0000000000000796 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM35647786X | ||
| 035 | |a (NLM)37144557 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pihlstrom, Nicole |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineering strategies of Anti-HIV antibody therapeutics in clinical development |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2023 | ||
| 500 | |a Date Revised 03.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a PURPOSE OF REVIEW: Anti-human immunodeficiency virus (HIV) antibody-based therapeutics offer an alternative treatment option to current antiretroviral drugs. This review aims to provide an overview of the Fc- and Fab-engineering strategies that have been developed to optimize broadly neutralizing antibodies and discuss recent findings from preclinical and clinical studies | ||
| 520 | |a RECENT FINDINGS: Multispecific antibodies, including bispecific and trispecific antibodies, DART molecules, and BiTEs, as well as Fc-optimized antibodies, have emerged as promising therapeutic candidates for the treatment of HIV. These engineered antibodies engage multiple epitopes on the HIV envelope protein and human receptors, resulting in increased potency and breadth of activity. Additionally, Fc-enhanced antibodies have demonstrated extended half-life and improved effector function | ||
| 520 | |a SUMMARY: The development of Fc and Fab-engineered antibodies for the treatment of HIV continues to show promising progress. These novel therapies have the potential to overcome the limitations of current antiretroviral pharmacologic agents by more effectively suppressing viral load and targeting latent reservoirs in individuals living with HIV. Further studies are needed to fully understand the safety and efficacy of these therapies, but the growing body of evidence supports their potential as a new class of therapeutics for the treatment of HIV | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a HIV Antibodies |2 NLM | |
| 700 | 1 | |a Bournazos, Stylianos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in HIV and AIDS |d 2006 |g 18(2023), 4 vom: 01. Juli, Seite 184-190 |w (DE-627)NLM182527514 |x 1746-6318 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:4 |g day:01 |g month:07 |g pages:184-190 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/COH.0000000000000796 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 4 |b 01 |c 07 |h 184-190 | ||